Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Tokyo, – February 3, 2011 – Astellas Pharma Inc. (TSE: 4503) announced today that it has established Astellas Pharma Australia Pty Ltd (“Astellas Australia”), in North Ryde (near Sydney),...
Read more about Astellas to Establish Sales Affiliate in Australia
Tokyo, December 20, 2010 - Astellas Pharma Inc. (“Astellas”; headquarter: Tokyo; President and CEO: Masafumi Nogimori) announced today that it agreed with AstraZeneca UK Limited upon an...
Tokyo, December 10, 2010 - Astellas Pharma Inc. (“Astellas”; Headquarters: Tokyo, President & CEO: Masafumi Nogimori) today announced that a new organization is to be established within...
Read more about Astellas Pharma Inc. to Promote Employment of Differently Abled People
Maruho Co., Ltd. （Headquarters: Osaka, President & CEO: Koichi Takagi, hereafter referred to “Maruho”) and Astellas Pharma Inc. (Headquarters: Tokyo, President & CEO: Masafumi Nogimori,...
Tokyo, November 24, 2010 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori) today announced the new corporate name of merged production subsidiary. As announced on...
TOKYO, November, 1, 2010—Astellas Pharma Inc. (TSE: 4503; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it entered into a definitive option agreement with...
Tokyo, October 28, 2010 - Astellas Pharma Inc. (headquarters: Tokyo; President and CEO: Masafumi Nogimori; “Astellas”) and its US affiliate Astellas US LLC (headquarters: Deerfield, IL;...
Tokyo, October 28, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it submitted a market authorization application for...
Tokyo, October, 25, 2010—Astellas Pharma Inc. (“Astellas”; President and CEO: Masafumi Nogimori) announced that the “Flying Star Fund,” a social contribution fund run by employees, has...
Tokyo and Akita, Japan, September 30, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) and UMN Pharma Inc. (“UMN Pharma”; headquarters:...
Zeria Pharmaceutical Co., Ltd. (Headquarters: Chuo-ku, Tokyo; President and CEO: Sachiaki Ibe; “Zeria”) and Astellas Pharma Inc. (Headquarters: Chuo-ku, Tokyo; President and CEO: Masafumi...
Read more about Announcement of the NDA submission of Z-338 /YM443 for functional dyspepsia in Japan
Tokyo, September 29, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced that it submitted a market authorization application for...
Osaka and Tokyo, Japan, September 10, 2010 - Ono Pharmaceutical Co., Ltd. (“Ono”; headquarters: Osaka; President and Representative Director: Gyo Sagara) and Astellas Pharma Inc....
Tokyo, Japan, September 8, 2010 - Astellas Pharma Inc. (“Astellas”; headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced the donation of three high-standard ambulances to local...
Read more about Donation of Ambulances on First-Aid Day (September 9)
Astellas Pharma Inc. and its US subsidiary, Astellas Pharma US, Inc. ("Astellas") and Teva Pharmaceutical USA, Inc. ("Teva") announced today that the three companies have reached an agreement to...
Read more about Astellas and Teva Reached a Settlement Agreement on VESIcare® Patent Case
Follow us
